Anemia (Blood Loss) and Polycythemia — Clinical Documentation Guide (2026)

This Clinical Documentation Guide (CDG) provides AAPC/AHIMA-credentialed coders and clinical documentation integrity (CDI) specialists with comprehensive coding, clinical, and documentation guidance for anemias — with a focus on blood loss anemia — and polycythemia. Content reflects FY2026 ICD-10-CM guidelines (effective October 1, 2025 – September 30, 2026) and incorporates current clinical, risk adjustment, and CDI query standards. Use this guide to ensure accurate diagnosis code assignment, defensible documentation, and appropriate CDI query triggers across all inpatient and outpatient care settings.

🔍 1. Definition

Anemia is a condition in which the number of red blood cells (RBCs) or the hemoglobin concentration within them is lower than normal, impairing the blood's ability to carry adequate oxygen to the body's tissues. The World Health Organization (WHO) defines anemia as hemoglobin below 13 g/dL in adult males, below 12 g/dL in non-pregnant adult females, and below 11 g/dL in pregnant women. Anemia may result from blood loss, decreased RBC production, or increased RBC destruction, and its clinical significance varies widely from asymptomatic laboratory findings to life-threatening hemorrhagic shock.

Anemia due to blood loss — the primary focus of this guide — is subdivided by acuity:

• Acute posthemorrhagic anemia (D62): Anemia resulting from sudden, significant blood loss (e.g., trauma, surgical hemorrhage, GI bleeding event, ruptured aneurysm). The rapid decline in circulating RBC mass outpaces compensatory erythropoiesis. Clinical criteria require physician documentation linking anemia to acute blood loss, supported by a sustained hemoglobin/hematocrit decline, as outlined in AHA Coding Clinic, 3Q 2019.
• Iron deficiency anemia secondary to blood loss, chronic (D50.0): Long-standing blood loss (e.g., chronic GI bleeding, heavy menstrual periods, esophageal varices) depletes iron stores over time, resulting in microcytic, hypochromic anemia.

Anemia in chronic disease encompasses several distinct etiologies: anemia associated with neoplastic disease (D63.0), anemia in chronic kidney disease (D63.1), anemia in other chronic diseases (D63.8), and drug-induced anemia (D64.81). Each requires documentation of the underlying condition and its causal relationship to the anemia.

Polycythemia is the opposite condition — an abnormal increase in the total red blood cell mass, leading to elevated hematocrit and blood viscosity. It is classified as primary (polycythemia vera, D45), secondary (reactive elevation from hypoxia, EPO excess, or other causes; D75.1), familial/hereditary (D75.0), or neonatal (P61.1). Polycythemia vera is classified as a neoplasm of uncertain behavior by ICD-10-CM and carries significant risk adjustment weight.

🗂️ 2. Alternative Terminology

🩺 3. Signs & Symptoms

Anemia (Blood Loss)

Clinical presentation depends on acuity and severity of blood loss. Per StatPearls (NCBI), anemia due to blood loss presents with:

• Fatigue and generalized weakness — most common presenting symptom; disproportionate to activity level
• Pallor — particularly of conjunctiva, nail beds, and palmar creases
• Tachycardia and palpitations — compensatory response to reduced oxygen-carrying capacity
• Dyspnea on exertion — worsening with progressive anemia
• Dizziness/lightheadedness/syncope — especially with acute blood loss and volume depletion
• Hypotension — in acute hemorrhagic cases; may progress to hemorrhagic shock
• Tachypnea — compensatory respiratory response
• Decreased urine output — in hypovolemic states from acute blood loss
• Koilonychia (spoon nails) and glossitis — classic signs of chronic iron deficiency anemia
• Pica — craving for non-food items (ice, clay, dirt) seen in severe iron deficiency

Polycythemia

• Pruritus after bathing (aquagenic pruritus) — characteristic of polycythemia vera; present in ~40% of PV patients
• Plethora (facial redness/ruddy complexion) — due to increased RBC mass and skin hyperemia
• Headache, dizziness, and visual disturbances — from hyperviscosity and reduced cerebral blood flow
• Splenomegaly — palpable in 70–90% of PV patients from extramedullary hematopoiesis
• Thrombotic events (DVT, stroke, MI, Budd-Chiari syndrome) — major complications from hyperviscosity
• Erythromelalgia — burning pain/redness of hands and feet due to platelet-mediated microvascular occlusion
• Gout — from elevated uric acid due to increased cell turnover
• Hypertension — common comorbidity in PV
• Bleeding tendency — paradoxically, despite elevated platelets, qualitative platelet dysfunction can cause GI bleeding

🧭 4. Differential Diagnosis

📋 5. Clinical Indicators for Coders/CDI

🦴 6. Anatomy & Pathophysiology

Erythropoiesis and Red Blood Cell Physiology

Red blood cells (erythrocytes) are produced in the bone marrow via erythropoiesis, a process regulated primarily by erythropoietin (EPO), a glycoprotein hormone produced by peritubular cells of the renal cortex in response to tissue hypoxia. Normal RBC lifespan is approximately 120 days; aged or damaged cells are cleared by splenic macrophages. The average adult has approximately 5 million RBCs/μL and 14–17 g/dL hemoglobin (males) or 12–15 g/dL (females), per StatPearls.

Pathophysiology of Blood Loss Anemia

In acute hemorrhage, intravascular volume and RBC mass fall simultaneously. Initially, hematocrit may appear normal due to proportional plasma loss; over 24–72 hours, compensatory hemodilution from fluid shifts and volume replacement causes the true extent of RBC loss to manifest as a measured anemia. The bone marrow responds with increased erythropoiesis (reticulocytosis) within 3–5 days, but cannot replace acute losses rapidly.

In chronic blood loss, the sustained but slower hemorrhage gradually depletes iron stores (ferritin → serum iron → bone marrow iron → TIBC elevation → hemoglobin fall), producing the classic microcytic hypochromic pattern of iron deficiency anemia (D50.0). Common chronic sources include peptic ulcer disease, colorectal polyps/cancer, celiac disease, hookworm infestation, and menorrhagia.

Pathophysiology of Polycythemia Vera

Polycythemia vera is a clonal myeloproliferative neoplasm driven by an acquired somatic mutation in the JAK2 gene — the JAK2 V617F point mutation is present in >95% of PV patients, as documented by the NCCN Guidelines for Myeloproliferative Neoplasms. This mutation results in constitutive activation of the JAK-STAT signaling pathway, causing EPO-independent proliferation of erythroid precursors. The resulting increase in RBC mass elevates blood viscosity, promoting thrombosis. Long-term, PV may progress to myelofibrosis (spent phase) or acute myeloid leukemia (AML) in ~10–20% of patients over 20 years.

Pathophysiology of Secondary Polycythemia

Secondary polycythemia (D75.1) reflects an appropriate physiological response to chronic hypoxia (COPD, OSA, cyanotic heart disease, high altitude) or inappropriate EPO overproduction (renal cell carcinoma, hepatocellular carcinoma, cerebellar hemangioblastoma). Unlike PV, EPO levels are elevated (or inappropriately normal), JAK2 is negative, and thrombotic risk is generally lower. Correction of the underlying cause typically resolves the erythrocytosis.

💊 7. Medication Impact / Treatment

Anemia Treatment

• Blood transfusion (PRBC): First-line for symptomatic acute anemia; typically indicated when Hgb < 7–8 g/dL or with cardiovascular compromise. Coded with CPT 36430 and HCPCS P9011 (PRBCs) or P9016 (leukocyte-reduced RBCs).
• Oral iron supplementation: First-line for iron deficiency anemia when GI tolerated (ferrous sulfate 325 mg TID). No specific CPT or HCPCS; pharmacy dispensed.
• IV iron therapy: Used when oral iron is intolerable or malabsorbed, or in CKD patients on dialysis. Key HCPCS codes include J1750 (iron dextran), J1439 (ferric carboxymaltose, Injectafer), and J1437 (iron sucrose). Administration coded with CPT 96372 (IV/IM injection) or appropriate infusion code.
• Erythropoiesis-stimulating agents (ESAs): Epoetin alfa (J0881 per 1,000 units) and darbepoetin alfa (J0885 per 25 mcg) stimulate RBC production. Indicated for anemia of CKD (D63.1) and in select cancer-related anemias (D63.0); NOT indicated for iron deficiency or acute blood loss anemia. CMS LCD L34375 governs Medicare ESA coverage requirements — documentation must establish Hgb < 10 g/dL and clinical indication.
• Drug-induced anemia cessation: When D64.81 applies, the causative agent should be identified; adverse effect codes from T36–T50 (with 5th/6th character 5) are added per ICD-10-CM instructions.

Polycythemia Treatment

• Phlebotomy (therapeutic): First-line for PV to maintain hematocrit < 45%. CPT 36415 (venipuncture) may apply; document as therapeutic phlebotomy for blood viscosity management.
• Cytoreductive therapy: Hydroxyurea (first-line cytoreduction for high-risk PV), ruxolitinib (JAK1/2 inhibitor for hydroxyurea-intolerant/refractory PV per NCCN), interferon-alpha. Reported with appropriate evaluation/management codes.
• Aspirin (low-dose): Reduces thrombotic risk in PV; typically 81–100 mg/day.
• Splenectomy: Occasionally performed for PV with massive, symptomatic splenomegaly or in late-stage myelofibrotic transformation. CPT codes 38100 (splenectomy total, laparotomy approach) or 38101 (partial), 38102 (total, en bloc), 38115 (repair of ruptured spleen). More commonly performed for hereditary hemolytic anemias (e.g., hereditary spherocytosis) than for PV.
• Partial exchange transfusion: Used in neonatal polycythemia (P61.1) to reduce hematocrit safely.

Preview ends here. The full guide continues with FY2026 ICD-10-CM code sets, CPT surgical coding, MS-DRG mapping, reimbursement guidance, CDI query templates, and an audit checklist — all available to CCO Members.

← Back to All Clinical Documentation Guides